Nuclear medicine in the detection and management of pancreatic islet-cell tumours
- 30 June 2005
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 19 (2) , 213-227
- https://doi.org/10.1016/j.beem.2004.09.001
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology groupSeminars in Nuclear Medicine, 2002
- Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine TumorsJournal of Clinical Endocrinology & Metabolism, 2001
- DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and TherapyEndocrinology, 1999
- Surgery to Cure the Zollinger–Ellison SyndromeNew England Journal of Medicine, 1999
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- 123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractNuclear Medicine and Biology, 1996
- [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validationLife Sciences, 1991
- Somatostatinoma: A case report and review of the literatureJournal of Surgical Oncology, 1987
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982